GlassScriptPhysician profile
Ajay Goel
NPI 1538159405
$8,284.74
in general payments reported to CMS, 2019-2025
31 companies · $923 in 2025
The $923 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $734 · 2020: $1,069 · 2021: $1,933 · 2022: $1,452 · 2023: $1,028 · 2024: $1,145 · 2025: $923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,039 · Education: $56.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,039.44 |
| Education | $56.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,516.22 | 2019-2025 | Stelara, Tremfya |
| Abbvie INC. | $1,447.71 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,211.12 | 2019-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $726.81 | 2019-2025 | Epclusa |
| Pfizer INC. | $612.14 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $442.99 | 2023-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $429.61 | 2019-2023 | Xifaxan, Plenvu |
| Phathom Pharmaceuticals, INC. | $206.50 | 2024-2025 | Voquezna |
| Braintree Laboratories, INC. | $183.38 | 2020-2023 | Sutab |
| Celgene Corporation | $170.99 | 2022-2024 | Zeposia |
| Medtronic, INC. | $167.46 | 2022 | |
| Merck Sharp & Dohme LLC | $165.40 | 2019-2024 | |
| Qol Medical, LLC | $139.59 | 2021-2025 | Sucraid |
| Madrigal Pharmaceuticals | $138.64 | 2024-2025 | Rezdiffra |
| Nestle Healthcare Nutrition INC. | $110.65 | 2020-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $109.19 | 2023-2024 | Ibsrela |
| Celltrion USA INC. | $98.65 | 2024-2025 | Zymfentra, Vegzelma |
| Allergan, INC. | $72.75 | 2019-2020 | |
| Boston Scientific Corporation | $38.55 | 2019-2021 | |
| Fujifilm Healthcare Americas Corporation | $33.99 | 2023 | Fujifilm |
| Intercept Pharmaceuticals, INC. | $33.09 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $32.65 | 2020-2025 | |
| Ipsen Biopharmaceuticals, INC | $32.31 | 2025 | Iqirvo |
| Harrow Eye, LLC | $30.83 | 2023-2025 | Iheezo |
| Teleflex LLC | $25.03 | 2024 | Titan Sgs |
| Aimmune Therapeutics, INC. | $23.76 | 2025 | Zenpep |
| Novo Nordisk INC | $23.03 | 2025 | Wegovy |
| Fresenius Kabi USA, LLC | $19.49 | 2023 | Idacio |
| Alfasigma USA, INC. | $18.14 | 2020 | |
| Ironwood Pharmaceuticals, INC | $13.14 | 2019 | |
| Ferring Pharmaceuticals INC. | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajay Goel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.